Enhabit, Inc. (EHAB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Enhabit, Inc. (EHAB) trades at $13.80 with AI Score 48/100 (Grade C). Enhabit, Inc. is a provider of home health and hospice services across 34 states in the United States. Market cap: $706.91M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026EHAB stock analysis for 2026: Analysts have set a consensus price target of $13.10 for Enhabit, Inc., suggesting 5.1% downside from the current price of $13.80. The AI MoonshotScore is 48/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
EHAB: the 1 perspectives are evenly split.
How is this calculated? →Enhabit, Inc. (EHAB) Healthcare & Pipeline Overview
Enhabit, Inc., operating as a standalone entity since 2022, delivers home health and hospice services across 34 states. With a focus on patient education, pain management, and palliative care, Enhabit addresses chronic conditions and end-of-life needs, positioning itself within the growing healthcare services sector.
What Is the Investment Thesis for EHAB?
Enhabit, Inc. presents a focused investment opportunity within the healthcare services sector, specifically in the growing home health and hospice market. The company's standalone operational structure, established in July 2022, allows for strategic focus and resource allocation to enhance its service offerings and expand its market presence. With a gross margin of 36.1%, Enhabit demonstrates potential for profitability improvements through operational efficiencies and strategic cost management. Growth catalysts include expanding its network of home health and hospice agencies and capitalizing on the increasing demand for in-home care services. However, the company's negative profit margin of -0.3% and a market capitalization of $706.91M indicate ongoing financial challenges that require careful monitoring.
Based on FMP financials and quantitative analysis
EHAB Key Highlights
- Operates 252 home health agencies and 99 hospice agencies across 34 states as of March 31, 2022, showcasing a broad geographic footprint.
- Gross margin of 36.1% indicates potential for profitability through efficient cost management.
- Standalone company since July 1, 2022, allowing for focused strategic initiatives and resource allocation.
- Offers a comprehensive suite of home health services, including specialized care for chronic diseases and post-operative rehabilitation.
- Provides hospice services encompassing pain management, counseling, and spiritual support for terminally ill patients and their families.
Who Are EHAB's Competitors?
EHAB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| NWKHY Netcare Limited | $7.17 | +0.00% | $843.64M | 50 |
| AONC American Oncology Network, Inc. | $10.00 | +0.00% | $292.48M | 50 |
| DCGO DocGo Inc. | $0.59 | +5.81% | $58.07M | 51 |
| JYNT The Joint Corp. | $9.16 | +2.10% | $130.55M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EHAB's Key Strengths?
- Wide geographic presence with operations in 34 states.
- Comprehensive service offerings, including home health and hospice care.
- Experienced management team with expertise in healthcare services.
- Established relationships with healthcare providers and referral sources.
What Are EHAB's Weaknesses?
- Negative profit margin indicates financial challenges.
- High operating costs associated with maintaining a large network of agencies.
- Dependence on government reimbursement programs.
- Intense competition in the home health and hospice market.
What Could Drive EHAB Stock Higher?
- Expansion of service offerings to include specialized care programs.
- Strategic partnerships with healthcare providers to expand referral network.
- Integration of technology to improve operational efficiency and patient care.
- Potential acquisitions of smaller home health and hospice agencies to expand market presence.
What Are the Key Risks for EHAB?
- Negative return on equity (-0.6%) — the business is not currently generating profit on shareholder capital.
- Changes in government regulations and reimbursement policies.
- Intense competition from other home health and hospice providers.
- Rising labor costs and workforce shortages.
- Litigation and regulatory scrutiny.
- Negative profit margin impacting financial stability.
What Are the Growth Opportunities for EHAB?
- Expansion of Home Health Services: Enhabit can capitalize on the growing demand for home health services by expanding its service offerings and geographic reach. The market for home healthcare is projected to reach $300 billion by 2028, driven by an aging population and increasing preference for in-home care. Enhabit can leverage its existing infrastructure and expertise to penetrate new markets and offer specialized services such as chronic disease management and post-acute care, enhancing its competitive position and revenue streams.
- Strategic Acquisitions: Enhabit can pursue strategic acquisitions of smaller home health and hospice agencies to expand its market presence and service capabilities. The fragmented nature of the industry provides opportunities to consolidate regional players and integrate them into Enhabit's network. By acquiring agencies with complementary service offerings or geographic coverage, Enhabit can enhance its competitive advantage and achieve economies of scale, driving revenue growth and profitability.
- Enhanced Technology Integration: Investing in advanced technology solutions can improve operational efficiency and enhance patient care. Implementing telehealth platforms, remote monitoring devices, and electronic health records can streamline workflows, reduce costs, and improve patient outcomes. By leveraging technology, Enhabit can differentiate itself from competitors and attract patients seeking innovative and convenient healthcare solutions. The market for telehealth is expected to reach $50 billion by 2025, presenting a significant growth opportunity for Enhabit.
- Partnerships with Healthcare Providers: Collaborating with hospitals, physician groups, and other healthcare providers can expand Enhabit's referral network and increase patient volume. By establishing partnerships with key stakeholders in the healthcare ecosystem, Enhabit can gain access to a broader patient base and enhance its reputation as a trusted provider of home health and hospice services. These partnerships can also facilitate the development of integrated care models that improve patient outcomes and reduce healthcare costs.
- Focus on Specialized Care Programs: Developing specialized care programs for specific patient populations, such as those with chronic diseases or post-surgical needs, can differentiate Enhabit from competitors and attract patients seeking specialized expertise. By offering tailored care plans and dedicated support services, Enhabit can improve patient outcomes, enhance patient satisfaction, and increase revenue per patient. These specialized programs can also attract referrals from physicians and other healthcare providers seeking specialized care for their patients.
What Opportunities Does EHAB Have?
- Expansion into new geographic markets.
- Strategic acquisitions of smaller home health and hospice agencies.
- Development of specialized care programs for specific patient populations.
- Integration of technology to improve operational efficiency and patient care.
What Threats Does EHAB Face?
- Changes in government regulations and reimbursement policies.
- Increased competition from other home health and hospice providers.
- Rising labor costs and workforce shortages.
- Potential for litigation and regulatory scrutiny.
What Are EHAB's Competitive Advantages?
- Established network of home health and hospice agencies across multiple states.
- Comprehensive range of services, including specialized care for chronic diseases and post-operative rehabilitation.
- Strong relationships with healthcare providers and referral sources.
- Expertise in navigating complex regulatory requirements and reimbursement processes.
What Does EHAB Do?
Enhabit, Inc., established in 2014 and headquartered in Dallas, Texas, emerged as a standalone company on July 1, 2022, after previously operating as Encompass Health Home Health Holdings, Inc. The company specializes in providing home health and hospice services across the United States, operating through 252 home health agencies and 99 hospice agencies as of March 31, 2022, spanning 34 states. Enhabit's home health services encompass a wide range of medical support, including patient education, pain management, wound care, cardiac rehabilitation, infusion therapy, and pharmaceutical administration. They also offer specialized practices for managing chronic diseases such as diabetes, hypertension, arthritis, Alzheimer's disease, and Parkinson's disease. Therapy services, including physical, occupational, and speech therapy, are integral to their home health offerings. Enhabit's hospice services provide comprehensive care for terminally ill patients and their families, focusing on pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement support. The company's mission is to meet the physical, emotional, spiritual, and psychosocial needs of patients and their families during challenging times.
What Products and Services Does EHAB Offer?
- Provides patient education to help individuals understand their health conditions and treatment plans.
- Offers pain management services to alleviate discomfort and improve quality of life.
- Delivers wound care and dressing changes to promote healing and prevent infections.
- Conducts cardiac rehabilitation programs to improve cardiovascular health.
- Administers infusion therapy and pharmaceutical treatments in the comfort of patients' homes.
- Offers skilled observation and assessment services to monitor patients' health status.
- Provides physical, occupational, and speech therapy services to improve mobility, function, and communication skills.
- Offers hospice services, including palliative care, counseling, and spiritual support for terminally ill patients and their families.
How Does EHAB Make Money?
- Generates revenue by providing home health services to patients in their homes.
- Earns income through hospice care services for terminally ill patients and their families.
- Receives payments from Medicare, Medicaid, private insurance companies, and direct patient payments.
- Operates through a network of home health and hospice agencies across multiple states.
What Industry Does EHAB Operate In?
Enhabit, Inc. operates within the medical care facilities industry, which is experiencing growth driven by an aging population and increasing preference for in-home healthcare services. The industry is characterized by a mix of large national providers and smaller regional players. Enhabit's focus on both home health and hospice services positions it to capture a significant share of the market. The competitive landscape includes other major players in the home healthcare and hospice sectors, requiring Enhabit to differentiate itself through service quality, geographic reach, and specialized care offerings.
Who Are EHAB's Key Customers?
- Individuals requiring medical care and support in their homes.
- Terminally ill patients seeking comfort and palliative care.
- Families of patients needing assistance with caregiving and emotional support.
- Healthcare providers referring patients for home health and hospice services.
Company Profile
Enhabit, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Dallas, US. The company is led by CEO Barbara Ann Jacobsmeyer. EHAB has traded publicly since 2022.
F-Score 5/9Financial Health
Enhabit, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.94 places it in the grey zone, a middle ground that warrants monitoring.
ROE -1%Key Financial Metrics
Return on equity for Enhabit, Inc. stands at -0.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.3%, showing how much profit it generates from its asset base. Its free cash flow yield is 11.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.56 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.5%, the inverse of the P/E and a quick read on earnings relative to price.
EHAB Valuation & Market Position
With a $706.91M market cap, Enhabit, Inc. sits in the small-cap segment of the market. Relative to its peer group, EHAB's quantitative score of 48/100 is below the peer average of 60/100.
FY2026 estForward Outlook
Wall Street analysts project Enhabit, Inc. revenue of about $1.10B for fiscal 2026, with EPS near $0.60. The estimate reflects 3 contributing analysts.
EHAB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Enhabit has seen a notable increase in insider buying, indicating confidence from leadership in the company's future prospects.
- Recent community sentiment has shifted positively as discussions highlight Enhabit's innovative healthcare solutions and their potential market impact.
- Analysts have noted a growing demand for home health services, which Enhabit is well-positioned to capitalize on.
- The company has received positive feedback from recent earnings calls, showcasing operational improvements and strategic initiatives.
Bear Case
- Some investors remain cautious due to concerns over regulatory changes that could impact the home health industry.
- Community sentiment reflects skepticism regarding the company's ability to scale operations effectively in a competitive market.
- Recent discussions highlight challenges with staffing and retention, which could hinder service delivery and growth.
- Market perception is mixed, with some viewing Enhabit's valuation as stretched given current industry uncertainties.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EHAB Latest News
EHAB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EHAB.
Price Targets
Consensus target: $13.10
EHAB MoonshotScore
What does this score mean?
The MoonshotScore rates EHAB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Barbara Ann Jacobsmeyer
Unknown
Barbara Ann Jacobsmeyer currently manages 10,600 employees at Enhabit, Inc. Further details regarding her career history, education, and previous roles are not available in the provided data. Her leadership is pivotal in guiding Enhabit's strategic direction and operational efficiency within the competitive healthcare services market. Her experience in managing a large workforce is critical for Enhabit's success.
Track Record: Details regarding Barbara Ann Jacobsmeyer's specific achievements, strategic decisions, and company milestones under her leadership are not available in the provided data. Assessing her impact on Enhabit's performance requires further information on key financial and operational metrics during her tenure.
Common Questions About EHAB (Healthcare)
What does Enhabit, Inc. do?
Enhabit, Inc. provides home health and hospice services across 34 states in the United States. Operating as a standalone entity since July 2022, Enhabit delivers patient-centered care through a network of 252 home health agencies and 99 hospice agencies (as of March 31, 2022). Their services encompass patient education, pain management, wound care, cardiac rehabilitation, and palliative care, addressing both chronic conditions and end-of-life needs. Enhabit aims to meet the physical, emotional, spiritual, and psychosocial needs of patients and their families.
What do analysts say about EHAB stock?
Analyst consensus on Enhabit, Inc. (EHAB) stock is currently unavailable due to limited data. Key valuation metrics such as price-to-earnings ratio and enterprise value-to-EBITDA are needed to assess the stock's relative value. Growth considerations include the company's ability to expand its service offerings, penetrate new markets, and improve its profit margin. Investors should monitor the company's financial performance and strategic initiatives to evaluate its long-term potential. A beta of 1.08 suggests the stock's volatility is similar to the market average.
What are the main risks for EHAB?
Enhabit, Inc. faces several risks, including changes in government regulations and reimbursement policies, which could impact its revenue and profitability. Intense competition from other home health and hospice providers may put pressure on pricing and market share. Rising labor costs and workforce shortages could increase operating expenses and limit the company's ability to provide services. Potential litigation and regulatory scrutiny could result in financial penalties and reputational damage. The company's negative profit margin also poses a significant financial risk.
What are the key factors to evaluate for EHAB?
Enhabit, Inc. (EHAB) holds an AI score of 48/100 (low). Analysts target $13.10 (-5%). Not financial advice.
How frequently does EHAB data refresh on this page?
EHAB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EHAB's recent stock price performance?
Enhabit, Inc. (EHAB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Wide geographic presence with operations in 34 states. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EHAB overvalued or undervalued right now?
Valuing Enhabit, Inc. (EHAB) requires multiple metrics. Analysts target $13.10 (-5%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying EHAB?
Before investing in Enhabit, Inc. (EHAB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for in-depth analysis.
- Analyst consensus and detailed competitor information are unavailable.